1. BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study. Issue 8 (3rd December 2020) Authors: Borthakur, Gautam; Ofran, Yishai; Tallman, Martin S.; Foran, James; Uy, Geoffrey L.; DiPersio, John F.; Showel, Margaret M.; Shimoni, Avichai; Nagler, Arnon; Rowe, Jacob M.; Altman, Jessica K.; Abraham, Michal; Peled, Amnon; Shaw, Stephen; Bohana‐Kashtan, Osnat; Sorani, Ella; Pereg, Yaron; Foley‐... Journal: Cancer Issue: Volume 127:Issue 8(2021) Page Start: 1246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗